Owkin's AI-designed OKN4395 enters the clinic: first patient dosed in Phase I

An end-to-end AI biotech using its K1.0 AI operating system to discover drug targets, select and develop assets, and run AI-optimized clinical trials, while also selling diagnostics.

AI trained on patient data can pick the right asset and optimize the trial around it, beating conventional clinical-development failure rates.

Over $300M raised, including an $80M Series B-1 from Bristol Myers Squibb in June 2022 (valuation ~$1.5B)

Founded in 2016 by oncologist Thomas Clozel and mathematician Jean-Philippe Vert, Owkin began as a medical-AI company running drug-trial analytics for pharma, with hospital data networks as the moat. It reached a $1B+ valuation with its June 2022 $80M round led by Bristol Myers Squibb.

The company licensed OKN4395, a first-in-class EP2/EP4/DP1 triple inhibitor developed from a decade of Idorsia discovery work, then used its K1.0 operating system to pick indications, design the study and set up digital-twin external control arms for early efficacy signals.

On 22 January 2025 the first patient was dosed in INVOKE (NCT06789172), a global Phase Ia/1b first-in-human trial of OKN4395 in advanced solid tumors — the first Owkin asset to reach the clinic under its own AI-optimized program, with combination cohorts alongside pembrolizumab.

Hospital data partnerships gave Owkin training data no US-only AI startup could match, especially in Europe's privacy-restricted setting.

Using AI to pick indications and subtype patients attacks the main cause of trial failure: testing in the wrong population.

Digital-twin external control arms shrink the control-group cost and time of Phase I.

Owning the asset, not just selling software, captures the upside if the trial works.

The deepest AI moat is data you can legally use: Owkin turned hospital partnerships into training data, then trial design — the asset mattered less than the system that chose it.

As of 30 January 2025, Owkin's INVOKE study is enrolling across sites, with Phase Ia dose escalation running and Phase Ib expansion cohorts planned in sarcoma, NSCLC, ovarian cancer and gastric cancer. The company continues to sell diagnostics and research services while advancing OKN4395 and additional AI-selected pipeline assets; the trial's first data will determine whether the AI-optimized thesis holds.